<?xml version="1.0" encoding="UTF-8"?>
<p id="p0130">The use of JAK inhibitors is associated with an increased risk of serious infection, herpes zoster virus reactivation, and VTE. However, recent studies show potential direct antiviral and anti-inflammatory effects in COVID-19, seemingly unique to ruxolitinib and baricitinib. Taken together, there are insufficient data at this time to fully characterize the risk of harm or benefit in SARS-CoV-2 infection.</p>
